Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 14, Issue 5, 2004, Pages 259-269

  Jastrzebska M ^a   Widecka, K ^a   Naruszewicz, M ^a   Ciechanowicz, A ^a   Janczak Bazan, A ^a   Foltynska A ^a   Goracy I ^a   Chetstowski, K ^a   Wesotowska, T ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

ACE (I D) genotype; Fibrinogen; Fibrinolysis; Hypertension; PAI 1 (4G 5G) genotype; Perindopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOSTATIC AGENT; PERINDOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ISOLATION; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FIBRINOGEN BLOOD LEVEL; GENOTYPE; HEMOSTASIS; HUMAN; MALE; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; SEX ROLE; STATISTICAL SIGNIFICANCE;

EID: 10044223303     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-4753(04)80053-X     Document Type: Article

References (43)

1. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE (1998) Effect of activation and inhibition of renin-angiotensin system on plasma PAI-1. Hypertension 32: 965-971
2. Brown NJ, Biais C, Gandhi SK, Adam A (1998) ACE Insertion/Deletion genotype affects bradykinin metabolism. J Cardiovasc Pharmacol 32: 373-377
3. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ (2000) Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102: 829-832
4. Martinez E, Puras A, Escribano J, et al (2000) Angiotensin-converting enzyme (ACE) gene polymorphism, serum ACE activity and blood pressure in Spanish-Mediterranean population. J Hum Hypertens 14: 131-135
5. Cambien F, Costerousse O, Tiret L, et al (1994) Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 90: 669-676
6. Pontremoli R, Ravera M, Viazzi F, et al (2000) Genetic polymorphism of the renin-angiotensin system organ damage in essential hypertension. Kidney Int 57: 561-569
7. Lindpaintner K, Pfeffer MA, Kreutz R, et al (1995) A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischaemic heart disease. N Engl J Med 332: 706-711
8. Pfohl M, Koch M, Prescod S, Haase KK, Häring HU, Karsch KR (1999) Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically study. Eur Heart J 20: 1318-1325
9. Agerholm-Larsen B, Nordestgaard BG, et al (1997) ACE gene polymorphism: ischemic heart disease and longevity in 10150 individuals. Circulation 95: 2358-2367
10. Wesotowska T, Torbus-Lisiecka B, Klimek K, et al (2000) Plasma angiotensin I converting enzyme activity in members of families with a positive history of ischaemic heart disease. Kardiol Pol 52: 1-6
11. Makris TK, Stravroulakis GA, Dafni UG, et al (2000) ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension. Am Heart J 140: 760-765
12. Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Wiliams GH, Vaughan DE (2001) Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol 21: 1071-1077
13. Margaglione M, Grandone E, Vecchione G, et al (1997) Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol 17: 2082-2087
14. Gerning NO, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ (1997) Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 17: 33-37
15. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP (1997) Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95: 59-62
16. Boekholdt SM, Bijsterveld NR, Moons AHM, Levi M, Büller R, Peters RJG (2001) Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulation 104: 3063
17. Prisco D, Fatini C, Battaglini B, et al (2000) Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res 30: 179-185
18. Matsubara Y, Hayakawa T, Tsuda T, et al (2000) Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 healthy Japanese population. Blood Coagul Fibrinolysis 11: 115-120
19. Moriyama Y, Ogawa H, Oshima S, et al (1998) Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction. Coronary Artery Dis 9: 691-696
20. Lottermoser K, Weisser B, Hertfelder HJ, Wöstmann, Vetter H, Düsing R (1998) Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens 11: 378-384
21. Ferrari P, Bianchi G (2000) The genomics of cardiovascular disorders. Therapeutic implications. Drugs 59: 1025-1042
22. Margaglione M, Grandone F, Cappucci G, et al (1997) An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 77: 605-606
23. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D (1995) Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 92: 31-38
24. Erdem Y, Usalan C, Haznedaroglu IC, et al (1999) Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 12: 1071-1076
25. Poli KA, Tofler GH, Larson MG, et al (2000) Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 101: 264-269
26. Gibbs CR, Blann AD, Watson RDS, Lip GYH (2001) Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Effects of angiotensin-converting enzyme inhibitor and β-blocker therapy. Circulation 103: 1746-1751
27. Pahor M, Franse LV, Deitcher SR, et al (2002) Fosinopril versus amlodipine comparative treatments study. A randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 105: 457-461
28. Li-Saw-Hee FL, Beevers DG, Lip GYH (2001) Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Intern J Cardiol 78: 241-246
29. Tom B, de Vries R, Saxena PR, Danser AHJ (2001) Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N- domain blockade. Hypertension 38: 95-99
30. Ueda S, Meredith PA, Morton JJ, Connell JMC, Elliott HL (1998) ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 98: 2148-2153
31. King SJ, Oparil S (1992) Converting-enzyme inhibitors increase converting enzyme mRNA and activity in endothelial cells. Am J Physiol 263: C743-C749
32. Sung-Kyu Ha, Seung Yong Lee, Hong Su Park, et al (2000) ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors with proteinuric non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 15: 1617-1623
33. Zhuo JL, Mendelsohn FAO, Ohishi M (2002) Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 39 (part 2): 634-638
34. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE (2000) Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102: 2190-2196
35. Kimura H, Gejyo F, Suzuki Y, Suzuki S, Miyazaki R, Arakawa M (1998) Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy. Kidney Int 54: 1659-1669
36. Viitanen L, Pihlajamäki J, Halonen P, et al (2001) Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis 157: 57-64
37. Margaglione M, Cappucci G, Colaizzo D, et al (1998) The PAI-1 gene locus 4G/5G polymorphism is associated with family history of coronary artery disease. Arterioscler Thromb Vasc Biol 18: 152-156
38. Festa A, D'Agostino R, Rich SS, Jenny NS, Tracy RP, Haffner SM (2003) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Circulation 107: 2422
39. Jastrzȩbska M, Gora̧cy I, Naruszewicz M (2003) Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension. Thromb Res 110: 339-344
40. Minai K, Matsumoto T, Horie H, et al (2001) Bradykinin stymulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin converting enzyme inhibitors. J Am Coll Cardiol 37: 1565-1570
41. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ (2003) Angiotensin converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 107: 579-585
42. Hojo Y, Ikeda U, Shimada K (2001) Effect of angiotensin converting enzyme inhibitor on plasma von Willebrand factor level in patients with coronary artery disease (Letter to the Editor). Cardiovasc Drugs Therapy 15: 91-92
43. Pedrinelli R, Giampietro O, Carmassi F, et al (1994) Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 344: 14-18